Explore › Finding
Finding improvement
Anti-miR-33 treatment produced a striking reduction in plasma triglycerides with a maximum 50% reduction at study termination, primarily from reduced VLDL-associated triglycerides, driven by simultaneous upregulation of fatty acid oxidation genes and downregulation of fatty acid synthesis genes — a finding not previously observed in mouse studies.
Effect size50% reduction in plasma triglycerides at 12 weeks
Follow-up12 weeks
ComparatorMismatch control antisense oligonucleotide (same dose, same schedule)
Effect summaryimprovement; 50% reduction in plasma triglycerides at 12 weeks

Connected entities

Interventions
Anti-miR-33 antisense oligonucleotide
Conditions
Hypertriglyceridemia
Outcomes
Plasma VLDL triglyceride measurement

Source

PMC3235584
Inhibition of miR-33a/b in non-human primates raises plasma HDL and reduces VLDL triglycerides
Read on PMC → · View in graph →